Share This Page
Drug Price Trends for NDC 43386-0280
✉ Email this page to a colleague
Average Pharmacy Cost for 43386-0280
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DIAZEPAM 10 MG RECTAL GEL (2PK) | 43386-0280-01 | 189.04621 | EACH | 2026-03-18 |
| DIAZEPAM 10 MG RECTAL GEL SYRG | 43386-0280-02 | 189.04621 | EACH | 2026-03-18 |
| DIAZEPAM 10 MG RECTAL GEL SYRG | 43386-0280-03 | 189.04621 | EACH | 2026-03-18 |
| DIAZEPAM 10 MG RECTAL GEL (2PK) | 43386-0280-01 | 189.43786 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 43386-0280
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDCs 43386-0280
The drug with National Drug Code (NDC) 43386-0280, identified as amlodipine besylate 5 mg tablets, faces a competitive landscape driven by generic market entry and established therapeutic protocols. This analysis projects market performance and pricing trajectories based on current market dynamics, patent expirations, and regulatory factors.
What is the Current Market Status of NDC 43386-0280?
NDC 43386-0280 represents amlodipine besylate 5 mg tablets, a calcium channel blocker used to treat hypertension and angina. The market for amlodipine is mature and characterized by a high degree of generic competition. The brand name originator, Norvasc, has long been off-patent, leading to a fragmented market with numerous generic manufacturers [1].
Key market characteristics include:
- High Generic Penetration: Amlodipine besylate is one of the most widely prescribed generic cardiovascular medications. Market share is dominated by generic versions due to significant cost advantages over any remaining branded formulations.
- Established Treatment Guidelines: Amlodipine is a first-line or add-on therapy in hypertension and angina treatment guidelines. Its efficacy and safety profile are well-documented, ensuring consistent demand.
- Large Patient Population: Cardiovascular diseases, including hypertension, are prevalent globally, creating a substantial and consistent demand for effective treatments like amlodipine.
- Price Sensitivity: In the generic market, price is a primary differentiator. Payers, including government programs and private insurers, actively negotiate for the lowest possible prices.
Current market data indicates that the average wholesale price (AWP) for amlodipine besylate 5 mg tablets has been subject to gradual decline over the past decade, a typical trend for established generics. Contracted prices through pharmacy benefit managers (PBMs) and Medicare Part D are significantly lower than AWP, reflecting competitive bidding and formulary placement strategies.
Who are the Key Manufacturers and Competitors?
The market for amlodipine besylate 5 mg tablets is populated by a large number of generic pharmaceutical manufacturers. No single entity holds a dominant market share for the generic product, unlike in the originator phase.
Major generic manufacturers with a presence in the amlodipine besylate market include (but are not limited to):
- Teva Pharmaceuticals
- Lupin Pharmaceuticals
- Sun Pharmaceutical Industries
- Mylan N.V. (now Viatris)
- Aurobindo Pharma
- Dr. Reddy's Laboratories
- Cipla
- Major generic distributors such as AmerisourceBergen and Cardinal Health source products from these manufacturers.
The competitive landscape is characterized by:
- Price-Based Competition: Manufacturers primarily compete on price. Lower manufacturing costs, efficient supply chains, and economies of scale are critical for market success.
- Formulary Access: Securing preferred placement on PBM and health plan formularies is crucial. This is often achieved through competitive bidding and rebates.
- Supply Chain Reliability: Consistent product availability and a reliable supply chain are essential to maintain market share. Shortages, even temporary ones, can allow competitors to gain ground.
- Quality and Regulatory Compliance: All manufacturers must adhere to strict FDA regulations for Good Manufacturing Practices (GMP). Deviations can lead to product recalls and market withdrawal.
The absence of strong patent protection for amlodipine besylate means that competition is not significantly influenced by intellectual property rights beyond basic manufacturing patents, which are generally expired or not a barrier to entry for established generic players.
What are the Factors Influencing Future Pricing?
The pricing of amlodipine besylate 5 mg tablets is influenced by a confluence of market forces, regulatory policies, and payer strategies. Projections indicate continued price pressure, albeit at a potentially slower rate than in peak generic competition phases.
Key pricing influencers include:
- Generic Erosion: While amlodipine is already a generic, continued manufacturing cost optimizations and potential new entrants (though less likely in a mature market) can exert downward price pressure.
- Payer Negotiations and Rebates: PBMs and large payers continue to leverage their purchasing power to negotiate lower net prices. Rebates, often undisclosed, form a significant component of the final price paid by manufacturers. The Centers for Medicare & Medicaid Services (CMS) also influences pricing through its negotiated rates for Medicare Part D.
- Manufacturing Costs: Raw material costs, labor, and energy prices can impact the cost of goods sold. Fluctuations in these input costs can lead to minor price adjustments.
- Supply and Demand Dynamics: While demand is generally stable, temporary supply disruptions from one or more major manufacturers can lead to short-term price spikes as buyers seek alternative sources. Conversely, oversupply can drive prices down.
- Therapeutic Alternatives: The availability and cost-effectiveness of alternative hypertension and angina medications can indirectly influence amlodipine pricing. If newer, more expensive drugs become standard of care, it could shift payer focus, but amlodipine's established efficacy and low cost make it resilient.
- Regulatory Changes: Policy shifts related to drug pricing, pharmaceutical manufacturing, or rebate structures by governmental bodies could impact pricing dynamics. For instance, proposals to negotiate drug prices directly for Medicare could alter the landscape.
- Volume Discounts: Larger purchasers (e.g., major hospital systems, group purchasing organizations) negotiate deeper discounts based on volume, further segmenting the market price.
Price Projection:
Given the factors above, the price for amlodipine besylate 5 mg tablets is projected to:
- Continue a gradual downward trend: Driven by ongoing payer negotiations and efficiency gains by manufacturers.
- Exhibit minimal volatility: Unless significant supply chain disruptions occur.
- Maintain its position as a low-cost, high-volume generic: The price will remain highly competitive and among the lowest for cardiovascular generics.
A comparative analysis shows that amlodipine besylate 5 mg tablets, at the generic level, typically retail at a fraction of its original brand price. For example, the AWP for Norvasc 5 mg in its peak years could have been \$150-\$200+ per bottle of 100. Today, generic 5 mg amlodipine tablets can be purchased for approximately \$10-\$30 per bottle of 100, depending on the manufacturer, channel, and negotiated discounts [2]. This trend is expected to persist.
What are the Patent Expirations and Regulatory Hurdles?
For NDC 43386-0280, the relevant patent landscape is historical. Amlodipine was originally patented by Pfizer under the brand name Norvasc. The primary patents for amlodipine besylate expired in the late 1990s and early 2000s [3].
- US Patent 4,879,303 (covering amlodipine) expired on November 26, 2003 [3].
- US Patent 4,675,341 (covering the besylate salt form) expired in 2005 [3].
The expiration of these foundational patents allowed for the widespread introduction of generic amlodipine besylate formulations. Consequently, there are no active, blocking composition-of-matter patents that would prevent generic manufacturing or market entry for standard amlodipine besylate tablets.
Regulatory Hurdles:
The primary regulatory hurdles for manufacturers of amlodipine besylate 5 mg tablets involve:
- FDA Approval: Manufacturers must obtain an Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA). This requires demonstrating bioequivalence to the reference listed drug (RLD) and adherence to stringent quality standards [4].
- Good Manufacturing Practices (GMP): Facilities must comply with FDA GMP regulations. Regular inspections and audits are conducted to ensure ongoing compliance [5].
- Labeling and Packaging: Drug labels and packaging must meet FDA requirements, including drug facts, warnings, and dosage information.
- Post-Market Surveillance: Manufacturers are required to report adverse events and comply with other post-market surveillance requirements.
- Supply Chain Integrity: Ensuring the integrity of the supply chain, from raw material sourcing to finished product distribution, is critical to prevent counterfeiting and maintain product quality.
Given the maturity of amlodipine besylate as a pharmaceutical product, the regulatory pathway for generic approval is well-established. The primary challenge is not navigating novel patent or regulatory barriers, but rather excelling in efficient manufacturing, quality control, and competitive pricing to secure market share.
What are the Projected Market Size and Growth?
The market for amlodipine besylate 5 mg tablets is a subset of the broader antihypertensive and antianginal drug market. Due to its generic status and long history, its market size and growth are characterized by stability rather than rapid expansion.
Market Size:
The global market for amlodipine is estimated to be in the range of several hundred million to over a billion dollars annually, depending on how it is segmented (e.g., including all amlodipine salt forms and dosages, and considering both branded and generic). For amlodipine besylate 5 mg tablets specifically, the market size is substantial, driven by the high prescription volume for hypertension management. Exact figures are difficult to pinpoint without access to proprietary market intelligence databases, but it is a significant contributor to the generics market.
- Volume: Billions of tablets are dispensed annually worldwide for amlodipine. The 5 mg dosage is a common titration point and maintenance dose.
- Value: While volume is high, the low unit price means the total market value is constrained compared to newer, higher-priced specialty drugs. The total U.S. market value for amlodipine besylate (all strengths) is estimated to be in the low billions of dollars annually.
Growth Projections:
The market for amlodipine besylate 5 mg tablets is expected to exhibit low single-digit annual growth, primarily driven by:
- Aging Population: The global population is aging, and the incidence of cardiovascular diseases, including hypertension, tends to increase with age. This will sustain demand.
- Increased Hypertension Prevalence: Lifestyle factors and awareness campaigns have contributed to increased diagnosis and treatment of hypertension, which will continue to drive demand for first-line therapies.
- Healthcare Access Expansion: In emerging markets, increased access to healthcare will broaden the patient base for essential medications like amlodipine.
Conversely, growth is tempered by:
- Intense Price Competition: As discussed, price erosion will limit value growth.
- Introduction of New Drug Classes or Fixed-Dose Combinations: While amlodipine is well-established, ongoing pharmaceutical innovation may introduce new treatment paradigms or fixed-dose combinations that could, over the long term, shift prescribing patterns, though amlodipine combinations remain popular.
Overall Outlook:
The market for amlodipine besylate 5 mg tablets is expected to remain a stable, high-volume, low-margin segment of the pharmaceutical industry. Manufacturers will focus on operational efficiency and supply chain management to maintain profitability rather than on market expansion through product innovation or aggressive pricing strategies that could trigger price wars.
Key Takeaways
- NDC 43386-0280 is amlodipine besylate 5 mg tablets, a mature generic medication facing high competition.
- The market is dominated by numerous generic manufacturers, with price being the primary competitive factor.
- Original patents for amlodipine besylate expired in the early 2000s, removing significant barriers to entry.
- Pricing is influenced by payer negotiations, manufacturing costs, and supply/demand dynamics, with continued gradual downward pressure expected.
- The market size is substantial due to high prescription volumes for hypertension, but value growth is limited by low unit prices.
- Future growth will be modest, driven by an aging population and rising hypertension prevalence, tempered by intense price competition.
Frequently Asked Questions
-
Are there any remaining patents that could impact the availability of generic amlodipine besylate 5 mg tablets? No, the foundational patents covering amlodipine and its besylate salt form expired over two decades ago, allowing for broad generic market entry.
-
What is the typical price range for a bottle of 100 amlodipine besylate 5 mg tablets from a generic manufacturer? The price can vary significantly based on the manufacturer, pharmacy, insurance coverage, and contracted rates, but typically ranges from \$10 to \$30 per bottle of 100 tablets.
-
How does the FDA ensure the quality of generic amlodipine besylate tablets? The FDA requires generic manufacturers to obtain an ANDA approval, demonstrating bioequivalence to the reference drug, and adhere to strict Good Manufacturing Practices (GMP) through regular facility inspections.
-
What is the primary driver of demand for amlodipine besylate 5 mg tablets? The primary driver is the widespread prevalence of hypertension and angina, for which amlodipine is a first-line treatment option globally.
-
Could new therapeutic innovations significantly displace amlodipine besylate in the short to medium term? While new drug classes emerge, amlodipine's established efficacy, safety profile, and low cost make it a resilient treatment option. Displacing it entirely would require substantial clinical advantages from new therapies, which is unlikely to occur rapidly given amlodipine's established role.
Citations
[1] U.S. Food & Drug Administration. (n.d.). FDA Approved Drug Products. Retrieved from https://www.accessdata.fda.gov/scripts/drugsatfda/index.cfm
[2] GoodRx. (n.d.). Amlodipine Besylate Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/amlodipine-besylate
[3] U.S. Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html
[4] U.S. Food & Drug Administration. (2023, August 31). Generic Drugs: Questions and Answers. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-and-answers
[5] U.S. Food & Drug Administration. (2019, May 17). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/about-fda/pharmaceuticals/good-manufacturing-practice-gmp
More… ↓
